2020 has been a difficult year for everyone. However, despite the many challenges, we can also look back on some milestone achievements. In our latest newsletter, we review some of our major highlights. Click the link to read our newsletter: http://bit.ly/3njT6nQ
Would you like to receive our next newsletter in your email? You can subscribe here: https://www.tricals.org/subscribe-to-our-newsletter/
We look forward to the new year in which we will undoubtedly achieve even more together. Together we will build our highway towards new therapies for ALS.
Relaterade nyheter
Apellis reports discontinuation of MERIDIAN study
Pharmaceutical company Apellis has announced the discontinuation of the open-label phase of […]
Recording of virtual meeting - Adherence and retention in ALS clinical trials
On March 22, 2023, TRICALS organised its first virtual meeting: ‘Adherence and retention […]
COURAGE-ALS trial discontinued due to disappointing results
The company Cytokinetics has announced early termination of the COURAGE-ALS study. An […]
TRICALS consensus statement on Tofersen
OPINION: The consensus view of TRICALS neurologists is that Tofersen shows clear […]